Abstract
Since the arrival of drug-eluting (called drug-eluding by some) technology a
few years ago with the promise of reducing restenosis, questions abound
surrounding the future of the stent market: After numerous clinical studies
and mixed cost-effectiveness results, how is drug-eluding technology expected
to peform in the future? What can companies do to best market this technology
in the healthcare system of the US and 6 other major world markets? What are
the market trends to watch that will determine growth in this field in the
coming years? What companies have already established a leadership position in
stents and what do start ups have to do to join them? Major World Markets for
Stents and The Economics of Drug Eluding Technology, written by Kalorama
Analyst Dr. Kenneth Krul, takes a hard look at these questions with economic
analysis unmatched by any resource.
The field of drug-eluting stents remains an exciting technological innovation
that will be a major part of cardiovascular intervention technologies over the
next ten years. This report provides a complete market assessment for coronary
stents broadly, with emphasis on the economics of drug-eluting stents.
Markets sizes and forecasts are divided in two product segments:
- Bare Metal (BMS)
- Drug Eluding Stents (DES)
As a world market analysis, the report covers markets in the following countries:
- U.S.
- France
- Germany
- UK
- Italy
- Spain
- Japan
This report considers the options that the current technologies present, the
progress that is being made in these fields, and the reception these new
products are likely to experience in the marketplace. In its brief lifetime
(BMSs having only emerged fully in the mid-1990s), the field of coronary
stents has shown that it can hold many surprises. Among the information in
this complete survey of the coronary stent market, the report
contains:
- Discussion of Restenosis and its Implications
- Major World Market Size for BMS and DES
- Statistics Driving Stent Usage
- Forecasts in Major World Markets to 2012
- The Economic Case for Drug-Eluting Stent Technologies and Applications
- Successful Marketing Strategies
- Profiles of Key Stent Companies
- Most Favorable Markets for Stent Manufacturers
- Nine Strategic Conclusions Essential to The Market
The analysis presented in this report is based on data from a combination of
company, government, industrial, institutional and private sources. It
includes information from extensive literature reviews, as well as interviews
and discussions with experts in the field, including experts in cardiology and
cardiac surgery, as well as pathologists, public health experts, research
scientists, and business development and marketing managers engaged in the
field.
|